Conversely, CRC patients with higher GAS1 expression showed a trend toward improved overall prognosis (Fig. 7F, 9-month PFS rates for high vs. low: 73.9 vs. 50.0%, p = 0.160). This evidence concerns the gene GAS1 and colorectal carcinoma.